[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fZVKZfPP3ApJPU0tjHPyS8bR5pTVJIdp2BgeFz9m8TC4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":85,"rows":92},"MedSIR",[4],56,false,19,1,24438,40,4,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Breast Cancer",18,{"name":18,"count":19},"Advanced Breast Cancer",13,{"name":21,"count":22},"Metastatic Breast Cancer",9,{"name":24,"count":25},"Triple Negative Breast Cancer",5,{"name":27,"count":12},"HER2-positive Breast Cancer",{"name":29,"count":30},"Breast Cancer Metastatic",3,{"name":32,"count":33},"Advanced HR+\u002FHER2- Breast Cancer",2,{"name":35,"count":33},"HER2-negative Breast Cancer",[37,42,47,52,57,62,67,72,77,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03161353","Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.","2023-11-01","Perjeta",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05810870","PIK3CA\u002FPTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin","2026-04","MEN1611",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT06604858","Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer","2026-08","Pembrolizumab",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06048718","T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases","2026-11","Trastuzumab-Deruxtecan",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT07178938","Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases","2026-11-30","Radiotracer targeting somatostatin receptor 2",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT06486883","Safety and Efficacy of T-DXd vs. CDK4\u002F6i-based ET as First-line Therapy of HR-positive and HER2-low\u002FUltralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype","2027-01","Trastuzumab deruxtecan",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06612203","Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+\u002FHER2- Advanced Breast Cancer","2027-02","Debio 0123 and Sacituzumab govitecan",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06315010","REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis","2027-03","Repotrectinib",{"nctId":78,"briefTitle":79,"date":75,"intervention":80},"NCT04733118","Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer","Trastuzumab and Pertuzumab (FDC SC) and T-DM1",{"nctId":82,"briefTitle":83,"date":84,"intervention":66},"NCT06172127","PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer","2027-04",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,125,143,161,179,227,272,339,387,450,480,531,564,605,638,674,702,724,746,766,784,806,824,842,860,881,908,926,944,962,980,998,1016,1034,1052,1078,1096,1118,1139,1157,1175,1214,1236,1254,1272,1297,1315,1339,1357,1375,1393,1411,1429,1456,1482,1500,1526,1550,1568,1593,1618,1636,1654,1672,1690,1708,1726,1751,1769,1787,1809,1827,1845,1870,1893,1929,1957,1975],{"intervention":94,"totalTrials":9,"cells":95},"Everolimus",{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":121,"NA":123},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":9,"soonestReadout":110},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":117},"NCT06382948","Elacestrant + Everolimus in Patients ER+\u002FHER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4\u002F6i.","RECRUITING",[89],"2027-09","2028-04","2024-12-05",240,[18,115,35,116],"ER-positive Breast Cancer","ESR1 Gene Mutation",[94,118,119,120],"Elacestrant","Auxiliary Medicinal Product - Dexamethasone","Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues",{"trials":122,"activeCount":98},[],{"trials":124,"activeCount":98},[],{"intervention":118,"totalTrials":9,"cells":126},{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":133,"PHASE4":139,"NA":141},{"trials":128,"activeCount":98},[],{"trials":130,"activeCount":98},[],{"trials":132,"activeCount":98},[],{"trials":134,"activeCount":9,"soonestReadout":110},[135],{"nctId":106,"briefTitle":107,"status":108,"phases":136,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":137,"interventions":138},[89],[18,115,35,116],[94,118,119,120],{"trials":140,"activeCount":98},[],{"trials":142,"activeCount":98},[],{"intervention":119,"totalTrials":9,"cells":144},{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":151,"PHASE4":157,"NA":159},{"trials":146,"activeCount":98},[],{"trials":148,"activeCount":98},[],{"trials":150,"activeCount":98},[],{"trials":152,"activeCount":9,"soonestReadout":110},[153],{"nctId":106,"briefTitle":107,"status":108,"phases":154,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":155,"interventions":156},[89],[18,115,35,116],[94,118,119,120],{"trials":158,"activeCount":98},[],{"trials":160,"activeCount":98},[],{"intervention":120,"totalTrials":9,"cells":162},{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":175,"NA":177},{"trials":164,"activeCount":98},[],{"trials":166,"activeCount":98},[],{"trials":168,"activeCount":98},[],{"trials":170,"activeCount":9,"soonestReadout":110},[171],{"nctId":106,"briefTitle":107,"status":108,"phases":172,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":173,"interventions":174},[89],[18,115,35,116],[94,118,119,120],{"trials":176,"activeCount":98},[],{"trials":178,"activeCount":98},[],{"intervention":180,"totalTrials":30,"cells":181},"Carboplatin",{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":221,"PHASE4":223,"NA":225},{"trials":183,"activeCount":98},[],{"trials":185,"activeCount":98},[],{"trials":187,"activeCount":33,"soonestReadout":40},[188,202,214],{"nctId":189,"briefTitle":190,"status":191,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":197},"NCT04464174","Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer","COMPLETED",[88],"2023-11-10","2020-10-08",54,[24],[198,199,200,180,201],"Ipatasertib","Capecitabine","Eribulin","Gemcitabine",{"nctId":38,"briefTitle":39,"status":203,"phases":204,"primaryCompletion":40,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":209},"ACTIVE_NOT_RECRUITING",[88],"2026-11-01","2017-06-26",377,[15],[41,210,211,180,212,213],"Herceptin","Docetaxel","Letrozole","Tamoxifen",{"nctId":48,"briefTitle":49,"status":203,"phases":215,"primaryCompletion":50,"completion":50,"start":216,"enrollment":217,"conditions":218,"interventions":219},[88],"2025-05-29",31,[15,24],[51,180,220],"Paclitaxel",{"trials":222,"activeCount":98},[],{"trials":224,"activeCount":98},[],{"trials":226,"activeCount":98},[],{"intervention":66,"totalTrials":30,"cells":228},{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":266,"PHASE4":268,"NA":270},{"trials":230,"activeCount":98},[],{"trials":232,"activeCount":98},[],{"trials":234,"activeCount":33,"soonestReadout":65},[235,244,256],{"nctId":82,"briefTitle":83,"status":203,"phases":236,"primaryCompletion":84,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":241},[88],"2029-06","2024-07-22",165,[27],[66,242,243],"Phesgo 1,200 MG \u002F 600 MG \u002F 30,000 UNT Per 15 ML","Phesgo 600 MG \u002F 600 MG \u002F 20,000 UNT in 10 mL",{"nctId":245,"briefTitle":246,"status":191,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":255},"NCT04420598","DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease",[88],"2021-09-30","2023-04-04","2020-05-25",41,[18,27,253,254],"Brain Metastases","Leptomeningeal Metastasis",[66],{"nctId":63,"briefTitle":64,"status":108,"phases":257,"primaryCompletion":65,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":264},[88],"2028-01","2025-06-30",200,[18,262,263],"Advanced Breast Carcinoma","Hormone Receptor Positive Breast Carcinoma",[66,265],"CDK4\u002F6i plus ET",{"trials":267,"activeCount":98},[],{"trials":269,"activeCount":98},[],{"trials":271,"activeCount":98},[],{"intervention":200,"totalTrials":273,"cells":274},6,{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":333,"PHASE4":335,"NA":337},{"trials":276,"activeCount":98},[],{"trials":278,"activeCount":98},[],{"trials":280,"activeCount":9,"soonestReadout":45},[281,291,295,302,313,323],{"nctId":282,"briefTitle":283,"status":191,"phases":284,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":290},"NCT03222856","Ph II Study of Pembrolizumab & Eribulin in Patients With HR+\u002FHER2- MBC Previously Treated With Anthracyclines & Taxanes",[88],"2018-10-31","2020-12-23","2017-12-14",44,[15],[51,200],{"nctId":189,"briefTitle":190,"status":191,"phases":292,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":293,"interventions":294},[88],[24],[198,199,200,180,201],{"nctId":43,"briefTitle":44,"status":203,"phases":296,"primaryCompletion":45,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":301},[88],"2027-07","2023-05-24",14,[15,18,21],[46,200],{"nctId":303,"briefTitle":304,"status":191,"phases":305,"primaryCompletion":306,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":312},"NCT02061085","Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment",[88],"2015-12","2013-07",53,[310,311],"Breast Neoplasm","Metastasis",[200],{"nctId":314,"briefTitle":315,"status":316,"phases":317,"primaryCompletion":318,"completion":318,"start":318,"enrollment":98,"conditions":319,"interventions":320},"NCT04826016","POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer","WITHDRAWN",[87,88],"2022-03-16",[18],[321,200,322],"POL6326","Nab paclitaxel",{"nctId":324,"briefTitle":325,"status":326,"phases":327,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":332},"NCT03795012","Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients","TERMINATED",[88],"2021-03-31","2019-04-30",22,[15],[200],{"trials":334,"activeCount":98},[],{"trials":336,"activeCount":98},[],{"trials":338,"activeCount":98},[],{"intervention":51,"totalTrials":12,"cells":340},{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":381,"PHASE4":383,"NA":385},{"trials":342,"activeCount":98},[],{"trials":344,"activeCount":98},[],{"trials":346,"activeCount":9,"soonestReadout":50},[347,351,364,377],{"nctId":282,"briefTitle":283,"status":191,"phases":348,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":349,"interventions":350},[88],[15],[51,200],{"nctId":352,"briefTitle":353,"status":191,"phases":354,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":362},"NCT04710628","Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents",[88],"2024-07-01","2026-02-16","2021-09-21",43,[360,361],"Metastatic Thymic Carcinoma","Thymoma Type B3",[51,363],"Lenvatinib 10 mg",{"nctId":365,"briefTitle":366,"status":326,"phases":367,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":375},"NCT04335305","Checkpoint Blockade in COVID-19 Pandemic",[88],"2021-03-08","2021-06-21","2020-04-09",12,[373,374],"COVID-19","Pneumonia, Viral",[376,51],"Tocilizumab",{"nctId":48,"briefTitle":49,"status":203,"phases":378,"primaryCompletion":50,"completion":50,"start":216,"enrollment":217,"conditions":379,"interventions":380},[88],[15,24],[51,180,220],{"trials":382,"activeCount":98},[],{"trials":384,"activeCount":98},[],{"trials":386,"activeCount":98},[],{"intervention":388,"totalTrials":12,"cells":389},"Fulvestrant",{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":444,"PHASE4":446,"NA":448},{"trials":391,"activeCount":98},[],{"trials":393,"activeCount":98},[],{"trials":395,"activeCount":9,"soonestReadout":435},[396,406,416,430],{"nctId":397,"briefTitle":398,"status":191,"phases":399,"primaryCompletion":400,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":404},"NCT02491983","Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer",[88],"2020-01","2015-08",486,[21],[405,388,212],"Palbociclib",{"nctId":407,"briefTitle":408,"status":191,"phases":409,"primaryCompletion":410,"completion":259,"start":411,"enrollment":412,"conditions":413,"interventions":414},"NCT04603183","ABemaciclib, ET ± paclItaxel in aGgressive HR+\u002FHER2- MBC trIaL",[88],"2024-06-30","2021-06-02",162,[29],[415,220,212,388],"Abemaciclib",{"nctId":417,"briefTitle":418,"status":191,"phases":419,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":425},"NCT04300790","Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]\u002FHER2[-] PIK3CA-mut Advanced BC Patients",[88],"2022-06-15","2025-03-16","2020-10-23",69,[15],[426,427,388,212,428,429,213],"Alpelisib","Metformin","Exemestane","Vildagliptin",{"nctId":431,"briefTitle":432,"status":433,"phases":434,"primaryCompletion":435,"completion":436,"start":437,"enrollment":438,"conditions":439,"interventions":442},"NCT07619066","A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive\u002FHER2-negative Advanced Breast Cancer Harboring HER2 Mutations.","NOT_YET_RECRUITING",[88],"2028-09-28","2028-11-28","2026-10-04",25,[18,440,441],"Hormone Receptor Positive \u002F HER2-negative Breast Cancer","HER2 Mutation",[443,388],"Zongertinib",{"trials":445,"activeCount":98},[],{"trials":447,"activeCount":98},[],{"trials":449,"activeCount":98},[],{"intervention":212,"totalTrials":12,"cells":451},{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":474,"PHASE4":476,"NA":478},{"trials":453,"activeCount":98},[],{"trials":455,"activeCount":98},[],{"trials":457,"activeCount":9,"soonestReadout":40},[458,462,466,470],{"nctId":397,"briefTitle":398,"status":191,"phases":459,"primaryCompletion":400,"completion":400,"start":401,"enrollment":402,"conditions":460,"interventions":461},[88],[21],[405,388,212],{"nctId":407,"briefTitle":408,"status":191,"phases":463,"primaryCompletion":410,"completion":259,"start":411,"enrollment":412,"conditions":464,"interventions":465},[88],[29],[415,220,212,388],{"nctId":38,"briefTitle":39,"status":203,"phases":467,"primaryCompletion":40,"completion":205,"start":206,"enrollment":207,"conditions":468,"interventions":469},[88],[15],[41,210,211,180,212,213],{"nctId":417,"briefTitle":418,"status":191,"phases":471,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":472,"interventions":473},[88],[15],[426,427,388,212,428,429,213],{"trials":475,"activeCount":98},[],{"trials":477,"activeCount":98},[],{"trials":479,"activeCount":98},[],{"intervention":481,"totalTrials":30,"cells":482},"Sacituzumab Govitecan",{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":525,"PHASE4":527,"NA":529},{"trials":484,"activeCount":98},[],{"trials":486,"activeCount":98},[],{"trials":488,"activeCount":9,"soonestReadout":506},[489,502,514],{"nctId":490,"briefTitle":491,"status":191,"phases":492,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":497,"interventions":498},"NCT05520723","Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED",[88],"2023-10-18","2025-11-05","2023-02-06",50,[24,15,32],[499,500,501],"Sacituzumab govitecan","Loperamide","Granulocyte Colony-Stimulating Factor",{"nctId":503,"briefTitle":504,"status":433,"phases":505,"primaryCompletion":506,"completion":258,"start":507,"enrollment":508,"conditions":509,"interventions":511},"NCT07367178","Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+\u002FHER2- Breast Cancer",[88],"2027-06","2026-07",30,[15,32,510],"Advanced Triple-Negative Breast Cancer",[481,512,513],"Atropine","G-CSF",{"nctId":515,"briefTitle":516,"status":316,"phases":517,"primaryCompletion":518,"completion":519,"start":45,"enrollment":98,"conditions":520,"interventions":522},"NCT07134556","Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC",[88],"2028-05-28","2028-12-28",[24,521],"PDL-1 Positive",[523,524,481],"Zimberelimab","Domvanalimab",{"trials":526,"activeCount":98},[],{"trials":528,"activeCount":98},[],{"trials":530,"activeCount":98},[],{"intervention":220,"totalTrials":30,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":558,"PHASE4":560,"NA":562},{"trials":534,"activeCount":98},[],{"trials":536,"activeCount":98},[],{"trials":538,"activeCount":9,"soonestReadout":50},[539,550,554],{"nctId":540,"briefTitle":541,"status":191,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":547},"NCT04408118","First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC",[88],"2023-12-07","2020-10-05",100,[21,18,24],[548,220,549],"Atezolizumab","Bevacizumab",{"nctId":407,"briefTitle":408,"status":191,"phases":551,"primaryCompletion":410,"completion":259,"start":411,"enrollment":412,"conditions":552,"interventions":553},[88],[29],[415,220,212,388],{"nctId":48,"briefTitle":49,"status":203,"phases":555,"primaryCompletion":50,"completion":50,"start":216,"enrollment":217,"conditions":556,"interventions":557},[88],[15,24],[51,180,220],{"trials":559,"activeCount":98},[],{"trials":561,"activeCount":98},[],{"trials":563,"activeCount":98},[],{"intervention":199,"totalTrials":30,"cells":565},{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":599,"PHASE4":601,"NA":603},{"trials":567,"activeCount":98},[],{"trials":569,"activeCount":98},[],{"trials":571,"activeCount":9,"soonestReadout":590},[572,576,586],{"nctId":189,"briefTitle":190,"status":191,"phases":573,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":574,"interventions":575},[88],[24],[198,199,200,180,201],{"nctId":577,"briefTitle":578,"status":316,"phases":579,"primaryCompletion":580,"completion":580,"start":581,"enrollment":98,"conditions":582,"interventions":583},"NCT05227131","Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer",[88],"2024-10","2022-05-15",[21,18,27],[584,585,199],"Margetuximab","Tucatinib",{"nctId":587,"briefTitle":588,"status":433,"phases":589,"primaryCompletion":590,"completion":591,"start":592,"enrollment":593,"conditions":594,"interventions":596},"NCT07494448","Phase Ib\u002FII Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer",[87,88],"2027-12-31","2028-05-31","2026-07-01",24,[595,15],"HER 2 Positive Advanced Breast Cancer",[597,585,199,598],"Zanidatamab","Eribulin Mesilate",{"trials":600,"activeCount":98},[],{"trials":602,"activeCount":98},[],{"trials":604,"activeCount":98},[],{"intervention":213,"totalTrials":30,"cells":606},{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":632,"PHASE4":634,"NA":636},{"trials":608,"activeCount":98},[],{"trials":610,"activeCount":98},[],{"trials":612,"activeCount":9,"soonestReadout":40},[613,617,621],{"nctId":38,"briefTitle":39,"status":203,"phases":614,"primaryCompletion":40,"completion":205,"start":206,"enrollment":207,"conditions":615,"interventions":616},[88],[15],[41,210,211,180,212,213],{"nctId":417,"briefTitle":418,"status":191,"phases":618,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":619,"interventions":620},[88],[15],[426,427,388,212,428,429,213],{"nctId":622,"briefTitle":623,"status":191,"phases":624,"primaryCompletion":625,"completion":625,"start":626,"enrollment":627,"conditions":628,"interventions":630},"NCT05659563","Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+\u002FHER2[-] & Ki67≥10%",[88],"2025-01-30","2023-07-20",92,[15,629],"Breast Cancer, Early-Onset",[631,213],"Giredestrant",{"trials":633,"activeCount":98},[],{"trials":635,"activeCount":98},[],{"trials":637,"activeCount":98},[],{"intervention":639,"totalTrials":33,"cells":640},"Niraparib oral",{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":668,"PHASE4":670,"NA":672},{"trials":642,"activeCount":98},[],{"trials":644,"activeCount":98},[],{"trials":646,"activeCount":9,"soonestReadout":258},[647,657],{"nctId":648,"briefTitle":649,"status":108,"phases":650,"primaryCompletion":258,"completion":258,"start":651,"enrollment":508,"conditions":652,"interventions":656},"NCT06180356","Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression",[88],"2024-12-03",[653,654,655],"Ovarian Cancer","Oligometastatic Disease","Serous Ovarian Tumor",[639],{"nctId":658,"briefTitle":659,"status":191,"phases":660,"primaryCompletion":661,"completion":662,"start":663,"enrollment":299,"conditions":664,"interventions":665},"NCT04240106","Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)",[88],"2022-11-17","2023-11-17","2020-06-15",[15,29],[666,667],"Niraparib","Aromatase Inhibitors",{"trials":669,"activeCount":98},[],{"trials":671,"activeCount":98},[],{"trials":673,"activeCount":98},[],{"intervention":415,"totalTrials":33,"cells":675},{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":696,"PHASE4":698,"NA":700},{"trials":677,"activeCount":98},[],{"trials":679,"activeCount":98},[],{"trials":681,"activeCount":9,"soonestReadout":690},[682,686],{"nctId":407,"briefTitle":408,"status":191,"phases":683,"primaryCompletion":410,"completion":259,"start":411,"enrollment":412,"conditions":684,"interventions":685},[88],[29],[415,220,212,388],{"nctId":687,"briefTitle":688,"status":108,"phases":689,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":694},"NCT05708235","A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive\u002FHER2-negative EBC Population",[88],"2028-06-30","2024-04-01",976,[15],[631,415,695],"Inavolisib",{"trials":697,"activeCount":98},[],{"trials":699,"activeCount":98},[],{"trials":701,"activeCount":98},[],{"intervention":631,"totalTrials":33,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":718,"PHASE4":720,"NA":722},{"trials":705,"activeCount":98},[],{"trials":707,"activeCount":98},[],{"trials":709,"activeCount":9,"soonestReadout":690},[710,714],{"nctId":687,"briefTitle":688,"status":108,"phases":711,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":712,"interventions":713},[88],[15],[631,415,695],{"nctId":622,"briefTitle":623,"status":191,"phases":715,"primaryCompletion":625,"completion":625,"start":626,"enrollment":627,"conditions":716,"interventions":717},[88],[15,629],[631,213],{"trials":719,"activeCount":98},[],{"trials":721,"activeCount":98},[],{"trials":723,"activeCount":98},[],{"intervention":585,"totalTrials":33,"cells":725},{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":740,"PHASE4":742,"NA":744},{"trials":727,"activeCount":98},[],{"trials":729,"activeCount":98},[],{"trials":731,"activeCount":9,"soonestReadout":590},[732,736],{"nctId":577,"briefTitle":578,"status":316,"phases":733,"primaryCompletion":580,"completion":580,"start":581,"enrollment":98,"conditions":734,"interventions":735},[88],[21,18,27],[584,585,199],{"nctId":587,"briefTitle":588,"status":433,"phases":737,"primaryCompletion":590,"completion":591,"start":592,"enrollment":593,"conditions":738,"interventions":739},[87,88],[595,15],[597,585,199,598],{"trials":741,"activeCount":98},[],{"trials":743,"activeCount":98},[],{"trials":745,"activeCount":98},[],{"intervention":56,"totalTrials":9,"cells":747},{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":749,"activeCount":98},[],{"trials":751,"activeCount":98},[],{"trials":753,"activeCount":9,"soonestReadout":55},[754],{"nctId":53,"briefTitle":54,"status":203,"phases":755,"primaryCompletion":55,"completion":55,"start":756,"enrollment":757,"conditions":758,"interventions":759},[88],"2024-06-05",28,[15,21],[56],{"trials":761,"activeCount":98},[],{"trials":763,"activeCount":98},[],{"trials":765,"activeCount":98},[],{"intervention":46,"totalTrials":9,"cells":767},{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":778,"PHASE4":780,"NA":782},{"trials":769,"activeCount":98},[],{"trials":771,"activeCount":98},[],{"trials":773,"activeCount":9,"soonestReadout":45},[774],{"nctId":43,"briefTitle":44,"status":203,"phases":775,"primaryCompletion":45,"completion":297,"start":298,"enrollment":299,"conditions":776,"interventions":777},[88],[15,18,21],[46,200],{"trials":779,"activeCount":98},[],{"trials":781,"activeCount":98},[],{"trials":783,"activeCount":98},[],{"intervention":76,"totalTrials":9,"cells":785},{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":800,"PHASE4":802,"NA":804},{"trials":787,"activeCount":98},[],{"trials":789,"activeCount":98},[],{"trials":791,"activeCount":9,"soonestReadout":75},[792],{"nctId":73,"briefTitle":74,"status":108,"phases":793,"primaryCompletion":75,"completion":111,"start":794,"enrollment":795,"conditions":796,"interventions":799},[88],"2025-06-27",20,[797,253,798],"NSCLC","ROS1 Gene Rearrangement",[76],{"trials":801,"activeCount":98},[],{"trials":803,"activeCount":98},[],{"trials":805,"activeCount":98},[],{"intervention":512,"totalTrials":9,"cells":807},{"EARLY_PHASE1":808,"PHASE1":810,"PHASE2":812,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":809,"activeCount":98},[],{"trials":811,"activeCount":98},[],{"trials":813,"activeCount":9,"soonestReadout":506},[814],{"nctId":503,"briefTitle":504,"status":433,"phases":815,"primaryCompletion":506,"completion":258,"start":507,"enrollment":508,"conditions":816,"interventions":817},[88],[15,32,510],[481,512,513],{"trials":819,"activeCount":98},[],{"trials":821,"activeCount":98},[],{"trials":823,"activeCount":98},[],{"intervention":513,"totalTrials":9,"cells":825},{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":836,"PHASE4":838,"NA":840},{"trials":827,"activeCount":98},[],{"trials":829,"activeCount":98},[],{"trials":831,"activeCount":9,"soonestReadout":506},[832],{"nctId":503,"briefTitle":504,"status":433,"phases":833,"primaryCompletion":506,"completion":258,"start":507,"enrollment":508,"conditions":834,"interventions":835},[88],[15,32,510],[481,512,513],{"trials":837,"activeCount":98},[],{"trials":839,"activeCount":98},[],{"trials":841,"activeCount":98},[],{"intervention":695,"totalTrials":9,"cells":843},{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":854,"PHASE4":856,"NA":858},{"trials":845,"activeCount":98},[],{"trials":847,"activeCount":98},[],{"trials":849,"activeCount":9,"soonestReadout":690},[850],{"nctId":687,"briefTitle":688,"status":108,"phases":851,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":852,"interventions":853},[88],[15],[631,415,695],{"trials":855,"activeCount":98},[],{"trials":857,"activeCount":98},[],{"trials":859,"activeCount":98},[],{"intervention":71,"totalTrials":9,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":875,"PHASE4":877,"NA":879},{"trials":863,"activeCount":98},[],{"trials":865,"activeCount":98},[],{"trials":867,"activeCount":9,"soonestReadout":70},[868],{"nctId":68,"briefTitle":69,"status":203,"phases":869,"primaryCompletion":70,"completion":870,"start":871,"enrollment":872,"conditions":873,"interventions":874},[87,88],"2027-10","2025-01-17",76,[18],[71],{"trials":876,"activeCount":98},[],{"trials":878,"activeCount":98},[],{"trials":880,"activeCount":98},[],{"intervention":882,"totalTrials":9,"cells":883},"Camizestrant",{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":902,"PHASE4":904,"NA":906},{"trials":885,"activeCount":98},[],{"trials":887,"activeCount":98},[],{"trials":889,"activeCount":9,"soonestReadout":894},[890],{"nctId":891,"briefTitle":892,"status":108,"phases":893,"primaryCompletion":894,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":900},"NCT07195227","Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer",[88],"2028-02","2028-03","2026-03-24",150,[899,15],"Hormon Receptor Positive Breast Cancer",[882,901],"Ribociclib",{"trials":903,"activeCount":98},[],{"trials":905,"activeCount":98},[],{"trials":907,"activeCount":98},[],{"intervention":901,"totalTrials":9,"cells":909},{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":911,"activeCount":98},[],{"trials":913,"activeCount":98},[],{"trials":915,"activeCount":9,"soonestReadout":894},[916],{"nctId":891,"briefTitle":892,"status":108,"phases":917,"primaryCompletion":894,"completion":895,"start":896,"enrollment":897,"conditions":918,"interventions":919},[88],[899,15],[882,901],{"trials":921,"activeCount":98},[],{"trials":923,"activeCount":98},[],{"trials":925,"activeCount":98},[],{"intervention":41,"totalTrials":9,"cells":927},{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":938,"PHASE4":940,"NA":942},{"trials":929,"activeCount":98},[],{"trials":931,"activeCount":98},[],{"trials":933,"activeCount":9,"soonestReadout":40},[934],{"nctId":38,"briefTitle":39,"status":203,"phases":935,"primaryCompletion":40,"completion":205,"start":206,"enrollment":207,"conditions":936,"interventions":937},[88],[15],[41,210,211,180,212,213],{"trials":939,"activeCount":98},[],{"trials":941,"activeCount":98},[],{"trials":943,"activeCount":98},[],{"intervention":210,"totalTrials":9,"cells":945},{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":950,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":947,"activeCount":98},[],{"trials":949,"activeCount":98},[],{"trials":951,"activeCount":9,"soonestReadout":40},[952],{"nctId":38,"briefTitle":39,"status":203,"phases":953,"primaryCompletion":40,"completion":205,"start":206,"enrollment":207,"conditions":954,"interventions":955},[88],[15],[41,210,211,180,212,213],{"trials":957,"activeCount":98},[],{"trials":959,"activeCount":98},[],{"trials":961,"activeCount":98},[],{"intervention":211,"totalTrials":9,"cells":963},{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":968,"PHASE3":974,"PHASE4":976,"NA":978},{"trials":965,"activeCount":98},[],{"trials":967,"activeCount":98},[],{"trials":969,"activeCount":9,"soonestReadout":40},[970],{"nctId":38,"briefTitle":39,"status":203,"phases":971,"primaryCompletion":40,"completion":205,"start":206,"enrollment":207,"conditions":972,"interventions":973},[88],[15],[41,210,211,180,212,213],{"trials":975,"activeCount":98},[],{"trials":977,"activeCount":98},[],{"trials":979,"activeCount":98},[],{"intervention":242,"totalTrials":9,"cells":981},{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":992,"PHASE4":994,"NA":996},{"trials":983,"activeCount":98},[],{"trials":985,"activeCount":98},[],{"trials":987,"activeCount":9,"soonestReadout":84},[988],{"nctId":82,"briefTitle":83,"status":203,"phases":989,"primaryCompletion":84,"completion":237,"start":238,"enrollment":239,"conditions":990,"interventions":991},[88],[27],[66,242,243],{"trials":993,"activeCount":98},[],{"trials":995,"activeCount":98},[],{"trials":997,"activeCount":98},[],{"intervention":243,"totalTrials":9,"cells":999},{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1010,"PHASE4":1012,"NA":1014},{"trials":1001,"activeCount":98},[],{"trials":1003,"activeCount":98},[],{"trials":1005,"activeCount":9,"soonestReadout":84},[1006],{"nctId":82,"briefTitle":83,"status":203,"phases":1007,"primaryCompletion":84,"completion":237,"start":238,"enrollment":239,"conditions":1008,"interventions":1009},[88],[27],[66,242,243],{"trials":1011,"activeCount":98},[],{"trials":1013,"activeCount":98},[],{"trials":1015,"activeCount":98},[],{"intervention":597,"totalTrials":9,"cells":1017},{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1028,"PHASE4":1030,"NA":1032},{"trials":1019,"activeCount":98},[],{"trials":1021,"activeCount":98},[],{"trials":1023,"activeCount":9,"soonestReadout":590},[1024],{"nctId":587,"briefTitle":588,"status":433,"phases":1025,"primaryCompletion":590,"completion":591,"start":592,"enrollment":593,"conditions":1026,"interventions":1027},[87,88],[595,15],[597,585,199,598],{"trials":1029,"activeCount":98},[],{"trials":1031,"activeCount":98},[],{"trials":1033,"activeCount":98},[],{"intervention":598,"totalTrials":9,"cells":1035},{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1037,"activeCount":98},[],{"trials":1039,"activeCount":98},[],{"trials":1041,"activeCount":9,"soonestReadout":590},[1042],{"nctId":587,"briefTitle":588,"status":433,"phases":1043,"primaryCompletion":590,"completion":591,"start":592,"enrollment":593,"conditions":1044,"interventions":1045},[87,88],[595,15],[597,585,199,598],{"trials":1047,"activeCount":98},[],{"trials":1049,"activeCount":98},[],{"trials":1051,"activeCount":98},[],{"intervention":1053,"totalTrials":9,"cells":1054},"bexmarilimab",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1072,"PHASE4":1074,"NA":1076},{"trials":1056,"activeCount":98},[],{"trials":1058,"activeCount":98},[],{"trials":1060,"activeCount":9,"soonestReadout":1065},[1061],{"nctId":1062,"briefTitle":1063,"status":433,"phases":1064,"primaryCompletion":1065,"completion":1066,"start":507,"enrollment":1067,"conditions":1068,"interventions":1070},"NCT07460986","A PHASE IB\u002FII STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA",[87,88],"2028-07","2028-10",278,[1069],"Sarcoma of Soft Tissue",[1053,1071],"Doxorubicin",{"trials":1073,"activeCount":98},[],{"trials":1075,"activeCount":98},[],{"trials":1077,"activeCount":98},[],{"intervention":1071,"totalTrials":9,"cells":1079},{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1084,"PHASE3":1090,"PHASE4":1092,"NA":1094},{"trials":1081,"activeCount":98},[],{"trials":1083,"activeCount":98},[],{"trials":1085,"activeCount":9,"soonestReadout":1065},[1086],{"nctId":1062,"briefTitle":1063,"status":433,"phases":1087,"primaryCompletion":1065,"completion":1066,"start":507,"enrollment":1067,"conditions":1088,"interventions":1089},[87,88],[1069],[1053,1071],{"trials":1091,"activeCount":98},[],{"trials":1093,"activeCount":98},[],{"trials":1095,"activeCount":98},[],{"intervention":61,"totalTrials":9,"cells":1097},{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1099,"activeCount":98},[],{"trials":1101,"activeCount":98},[],{"trials":1103,"activeCount":9,"soonestReadout":60},[1104],{"nctId":58,"briefTitle":59,"status":433,"phases":1105,"primaryCompletion":60,"completion":1106,"start":1107,"enrollment":1108,"conditions":1109,"interventions":1111},[88],"2028-12-31","2026-04-30",10,[1110,27],"Solid Tumors",[61],{"trials":1113,"activeCount":98},[],{"trials":1115,"activeCount":98},[],{"trials":1117,"activeCount":98},[],{"intervention":80,"totalTrials":9,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1121,"activeCount":98},[],{"trials":1123,"activeCount":98},[],{"trials":1125,"activeCount":9,"soonestReadout":75},[1126],{"nctId":78,"briefTitle":79,"status":203,"phases":1127,"primaryCompletion":75,"completion":895,"start":1128,"enrollment":1129,"conditions":1130,"interventions":1132},[88],"2021-08-05",393,[1131],"Early Breast Cancer",[80],{"trials":1134,"activeCount":98},[],{"trials":1136,"activeCount":98},[],{"trials":1138,"activeCount":98},[],{"intervention":265,"totalTrials":9,"cells":1140},{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1151,"PHASE4":1153,"NA":1155},{"trials":1142,"activeCount":98},[],{"trials":1144,"activeCount":98},[],{"trials":1146,"activeCount":9,"soonestReadout":65},[1147],{"nctId":63,"briefTitle":64,"status":108,"phases":1148,"primaryCompletion":65,"completion":258,"start":259,"enrollment":260,"conditions":1149,"interventions":1150},[88],[18,262,263],[66,265],{"trials":1152,"activeCount":98},[],{"trials":1154,"activeCount":98},[],{"trials":1156,"activeCount":98},[],{"intervention":443,"totalTrials":9,"cells":1158},{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1160,"activeCount":98},[],{"trials":1162,"activeCount":98},[],{"trials":1164,"activeCount":9,"soonestReadout":435},[1165],{"nctId":431,"briefTitle":432,"status":433,"phases":1166,"primaryCompletion":435,"completion":436,"start":437,"enrollment":438,"conditions":1167,"interventions":1168},[88],[18,440,441],[443,388],{"trials":1170,"activeCount":98},[],{"trials":1172,"activeCount":98},[],{"trials":1174,"activeCount":98},[],{"intervention":405,"totalTrials":30,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1178,"activeCount":98},[],{"trials":1180,"activeCount":98},[],{"trials":1182,"activeCount":98},[1183,1187,1197],{"nctId":397,"briefTitle":398,"status":191,"phases":1184,"primaryCompletion":400,"completion":400,"start":401,"enrollment":402,"conditions":1185,"interventions":1186},[88],[21],[405,388,212],{"nctId":1188,"briefTitle":1189,"status":191,"phases":1190,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":1194,"interventions":1195},"NCT03184090","Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC",[88],"2020-10-27","2017-06-28",33,[21],[405,1196],"Endocrine therapy",{"nctId":1198,"briefTitle":1199,"status":191,"phases":1200,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1207},"NCT03809988","PALbociclib Rechallenge in horMone Receptor-posItive\u002FHER2- Negative Advanced Breast Cancer (PALMIRA)",[88],"2022-11-30","2019-04-05",198,[15,18,1205,1206],"Hormone Receptor Positive Tumor","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",[405,1196],{"trials":1209,"activeCount":98},[],{"trials":1211,"activeCount":98},[],{"trials":1213,"activeCount":98},[],{"intervention":1196,"totalTrials":33,"cells":1215},{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1230,"PHASE4":1232,"NA":1234},{"trials":1217,"activeCount":98},[],{"trials":1219,"activeCount":98},[],{"trials":1221,"activeCount":98},[1222,1226],{"nctId":1188,"briefTitle":1189,"status":191,"phases":1223,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":1224,"interventions":1225},[88],[21],[405,1196],{"nctId":1198,"briefTitle":1199,"status":191,"phases":1227,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":1228,"interventions":1229},[88],[15,18,1205,1206],[405,1196],{"trials":1231,"activeCount":98},[],{"trials":1233,"activeCount":98},[],{"trials":1235,"activeCount":98},[],{"intervention":500,"totalTrials":9,"cells":1237},{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1248,"PHASE4":1250,"NA":1252},{"trials":1239,"activeCount":98},[],{"trials":1241,"activeCount":98},[],{"trials":1243,"activeCount":98},[1244],{"nctId":490,"briefTitle":491,"status":191,"phases":1245,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":1246,"interventions":1247},[88],[24,15,32],[499,500,501],{"trials":1249,"activeCount":98},[],{"trials":1251,"activeCount":98},[],{"trials":1253,"activeCount":98},[],{"intervention":501,"totalTrials":9,"cells":1255},{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1266,"PHASE4":1268,"NA":1270},{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":98},[],{"trials":1261,"activeCount":98},[1262],{"nctId":490,"briefTitle":491,"status":191,"phases":1263,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":1264,"interventions":1265},[88],[24,15,32],[499,500,501],{"trials":1267,"activeCount":98},[],{"trials":1269,"activeCount":98},[],{"trials":1271,"activeCount":98},[],{"intervention":1273,"totalTrials":9,"cells":1274},"Retifanlimab",{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1279,"PHASE3":1291,"PHASE4":1293,"NA":1295},{"trials":1276,"activeCount":98},[],{"trials":1278,"activeCount":98},[],{"trials":1280,"activeCount":98},[1281],{"nctId":1282,"briefTitle":1283,"status":191,"phases":1284,"primaryCompletion":1285,"completion":1286,"start":1287,"enrollment":16,"conditions":1288,"interventions":1290},"NCT04231981","Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)",[88],"2022-02-15","2022-08-26","2020-04-28",[1289],"Penile Cancer",[1273],{"trials":1292,"activeCount":98},[],{"trials":1294,"activeCount":98},[],{"trials":1296,"activeCount":98},[],{"intervention":363,"totalTrials":9,"cells":1298},{"EARLY_PHASE1":1299,"PHASE1":1301,"PHASE2":1303,"PHASE3":1309,"PHASE4":1311,"NA":1313},{"trials":1300,"activeCount":98},[],{"trials":1302,"activeCount":98},[],{"trials":1304,"activeCount":98},[1305],{"nctId":352,"briefTitle":353,"status":191,"phases":1306,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":1307,"interventions":1308},[88],[360,361],[51,363],{"trials":1310,"activeCount":98},[],{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":98},[],{"intervention":1316,"totalTrials":9,"cells":1317},"Datopotamab deruxtecan",{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1333,"PHASE4":1335,"NA":1337},{"trials":1319,"activeCount":98},[],{"trials":1321,"activeCount":98},[],{"trials":1323,"activeCount":98},[1324],{"nctId":1325,"briefTitle":1326,"status":316,"phases":1327,"primaryCompletion":1328,"completion":1328,"start":1329,"enrollment":98,"conditions":1330,"interventions":1332},"NCT06676917","Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases",[88],"2027-08","2025-06",[1331],"Non-small Cell Lung Cancer",[1316],{"trials":1334,"activeCount":98},[],{"trials":1336,"activeCount":98},[],{"trials":1338,"activeCount":98},[],{"intervention":548,"totalTrials":9,"cells":1340},{"EARLY_PHASE1":1341,"PHASE1":1343,"PHASE2":1345,"PHASE3":1351,"PHASE4":1353,"NA":1355},{"trials":1342,"activeCount":98},[],{"trials":1344,"activeCount":98},[],{"trials":1346,"activeCount":98},[1347],{"nctId":540,"briefTitle":541,"status":191,"phases":1348,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":1349,"interventions":1350},[88],[21,18,24],[548,220,549],{"trials":1352,"activeCount":98},[],{"trials":1354,"activeCount":98},[],{"trials":1356,"activeCount":98},[],{"intervention":549,"totalTrials":9,"cells":1358},{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1369,"PHASE4":1371,"NA":1373},{"trials":1360,"activeCount":98},[],{"trials":1362,"activeCount":98},[],{"trials":1364,"activeCount":98},[1365],{"nctId":540,"briefTitle":541,"status":191,"phases":1366,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":1367,"interventions":1368},[88],[21,18,24],[548,220,549],{"trials":1370,"activeCount":98},[],{"trials":1372,"activeCount":98},[],{"trials":1374,"activeCount":98},[],{"intervention":198,"totalTrials":9,"cells":1376},{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1381,"PHASE3":1387,"PHASE4":1389,"NA":1391},{"trials":1378,"activeCount":98},[],{"trials":1380,"activeCount":98},[],{"trials":1382,"activeCount":98},[1383],{"nctId":189,"briefTitle":190,"status":191,"phases":1384,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":1385,"interventions":1386},[88],[24],[198,199,200,180,201],{"trials":1388,"activeCount":98},[],{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":98},[],{"intervention":201,"totalTrials":9,"cells":1394},{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1399,"PHASE3":1405,"PHASE4":1407,"NA":1409},{"trials":1396,"activeCount":98},[],{"trials":1398,"activeCount":98},[],{"trials":1400,"activeCount":98},[1401],{"nctId":189,"briefTitle":190,"status":191,"phases":1402,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":1403,"interventions":1404},[88],[24],[198,199,200,180,201],{"trials":1406,"activeCount":98},[],{"trials":1408,"activeCount":98},[],{"trials":1410,"activeCount":98},[],{"intervention":376,"totalTrials":9,"cells":1412},{"EARLY_PHASE1":1413,"PHASE1":1415,"PHASE2":1417,"PHASE3":1423,"PHASE4":1425,"NA":1427},{"trials":1414,"activeCount":98},[],{"trials":1416,"activeCount":98},[],{"trials":1418,"activeCount":98},[1419],{"nctId":365,"briefTitle":366,"status":326,"phases":1420,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":1421,"interventions":1422},[88],[373,374],[376,51],{"trials":1424,"activeCount":98},[],{"trials":1426,"activeCount":98},[],{"trials":1428,"activeCount":98},[],{"intervention":1430,"totalTrials":9,"cells":1431},"Patritumab deruxtecan",{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1436,"PHASE3":1450,"PHASE4":1452,"NA":1454},{"trials":1433,"activeCount":98},[],{"trials":1435,"activeCount":98},[],{"trials":1437,"activeCount":98},[1438],{"nctId":1439,"briefTitle":1440,"status":191,"phases":1441,"primaryCompletion":1442,"completion":1443,"start":1444,"enrollment":1445,"conditions":1446,"interventions":1449},"NCT05865990","HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease",[88],"2024-11-29","2026-04-03","2023-11-24",63,[21,1447,1448],"Advanced Non-Small Cell Squamous Lung Cancer","Solid Tumor, Adult",[1430],{"trials":1451,"activeCount":98},[],{"trials":1453,"activeCount":98},[],{"trials":1455,"activeCount":98},[],{"intervention":1457,"totalTrials":9,"cells":1458},"Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib",{"EARLY_PHASE1":1459,"PHASE1":1461,"PHASE2":1463,"PHASE3":1476,"PHASE4":1478,"NA":1480},{"trials":1460,"activeCount":98},[],{"trials":1462,"activeCount":98},[],{"trials":1464,"activeCount":98},[1465],{"nctId":1466,"briefTitle":1467,"status":191,"phases":1468,"primaryCompletion":1469,"completion":1470,"start":1471,"enrollment":1472,"conditions":1473,"interventions":1474},"NCT03819010","Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -",[88],"2019-07-30","2019-12-31","2019-05-07",66,[15],[1457,1475],"Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib",{"trials":1477,"activeCount":98},[],{"trials":1479,"activeCount":98},[],{"trials":1481,"activeCount":98},[],{"intervention":1475,"totalTrials":9,"cells":1483},{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1494,"PHASE4":1496,"NA":1498},{"trials":1485,"activeCount":98},[],{"trials":1487,"activeCount":98},[],{"trials":1489,"activeCount":98},[1490],{"nctId":1466,"briefTitle":1467,"status":191,"phases":1491,"primaryCompletion":1469,"completion":1470,"start":1471,"enrollment":1472,"conditions":1492,"interventions":1493},[88],[15],[1457,1475],{"trials":1495,"activeCount":98},[],{"trials":1497,"activeCount":98},[],{"trials":1499,"activeCount":98},[],{"intervention":1501,"totalTrials":9,"cells":1502},"radium-223",{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1507,"PHASE3":1520,"PHASE4":1522,"NA":1524},{"trials":1504,"activeCount":98},[],{"trials":1506,"activeCount":98},[],{"trials":1508,"activeCount":98},[1509],{"nctId":1510,"briefTitle":1511,"status":191,"phases":1512,"primaryCompletion":1513,"completion":1514,"start":1515,"enrollment":1516,"conditions":1517,"interventions":1519},"NCT03002220","Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status",[88],"2020-05-06","2021-06-09","2016-12-21",52,[1518],"Prostate Cancer",[1501],{"trials":1521,"activeCount":98},[],{"trials":1523,"activeCount":98},[],{"trials":1525,"activeCount":98},[],{"intervention":1527,"totalTrials":9,"cells":1528},"CB-103",{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1544,"PHASE4":1546,"NA":1548},{"trials":1530,"activeCount":98},[],{"trials":1532,"activeCount":98},[],{"trials":1534,"activeCount":98},[1535],{"nctId":1536,"briefTitle":1537,"status":326,"phases":1538,"primaryCompletion":1539,"completion":1540,"start":1541,"enrollment":33,"conditions":1542,"interventions":1543},"NCT04714619","CB-103 Plus NSAI In Luminal Advanced Breast Cancer",[88],"2021-09-02","2022-04-26","2021-05-06",[18],[1527],{"trials":1545,"activeCount":98},[],{"trials":1547,"activeCount":98},[],{"trials":1549,"activeCount":98},[],{"intervention":584,"totalTrials":9,"cells":1551},{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1556,"PHASE3":1562,"PHASE4":1564,"NA":1566},{"trials":1553,"activeCount":98},[],{"trials":1555,"activeCount":98},[],{"trials":1557,"activeCount":98},[1558],{"nctId":577,"briefTitle":578,"status":316,"phases":1559,"primaryCompletion":580,"completion":580,"start":581,"enrollment":98,"conditions":1560,"interventions":1561},[88],[21,18,27],[584,585,199],{"trials":1563,"activeCount":98},[],{"trials":1565,"activeCount":98},[],{"trials":1567,"activeCount":98},[],{"intervention":1569,"totalTrials":9,"cells":1570},"Osimertinib",{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1575,"PHASE3":1587,"PHASE4":1589,"NA":1591},{"trials":1572,"activeCount":98},[],{"trials":1574,"activeCount":98},[],{"trials":1576,"activeCount":98},[1577],{"nctId":1578,"briefTitle":1579,"status":191,"phases":1580,"primaryCompletion":1581,"completion":1582,"start":1583,"enrollment":330,"conditions":1584,"interventions":1586},"NCT02841579","Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M",[88],"2018-12","2020-02-14","2016-09-02",[1585],"Non-Small Cell Lung Cancer",[1569],{"trials":1588,"activeCount":98},[],{"trials":1590,"activeCount":98},[],{"trials":1592,"activeCount":98},[],{"intervention":1594,"totalTrials":9,"cells":1595},"Irinotecan (CPT-11) liposome",{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1600,"PHASE3":1612,"PHASE4":1614,"NA":1616},{"trials":1597,"activeCount":98},[],{"trials":1599,"activeCount":98},[],{"trials":1601,"activeCount":98},[1602],{"nctId":1603,"briefTitle":1604,"status":191,"phases":1605,"primaryCompletion":1606,"completion":1607,"start":1608,"enrollment":1609,"conditions":1610,"interventions":1611},"NCT03328884","Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients",[88],"2018-08-31","2025-04-02","2017-05-02",55,[29],[1594],{"trials":1613,"activeCount":98},[],{"trials":1615,"activeCount":98},[],{"trials":1617,"activeCount":98},[],{"intervention":426,"totalTrials":9,"cells":1619},{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1624,"PHASE3":1630,"PHASE4":1632,"NA":1634},{"trials":1621,"activeCount":98},[],{"trials":1623,"activeCount":98},[],{"trials":1625,"activeCount":98},[1626],{"nctId":417,"briefTitle":418,"status":191,"phases":1627,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":1628,"interventions":1629},[88],[15],[426,427,388,212,428,429,213],{"trials":1631,"activeCount":98},[],{"trials":1633,"activeCount":98},[],{"trials":1635,"activeCount":98},[],{"intervention":427,"totalTrials":9,"cells":1637},{"EARLY_PHASE1":1638,"PHASE1":1640,"PHASE2":1642,"PHASE3":1648,"PHASE4":1650,"NA":1652},{"trials":1639,"activeCount":98},[],{"trials":1641,"activeCount":98},[],{"trials":1643,"activeCount":98},[1644],{"nctId":417,"briefTitle":418,"status":191,"phases":1645,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":1646,"interventions":1647},[88],[15],[426,427,388,212,428,429,213],{"trials":1649,"activeCount":98},[],{"trials":1651,"activeCount":98},[],{"trials":1653,"activeCount":98},[],{"intervention":428,"totalTrials":9,"cells":1655},{"EARLY_PHASE1":1656,"PHASE1":1658,"PHASE2":1660,"PHASE3":1666,"PHASE4":1668,"NA":1670},{"trials":1657,"activeCount":98},[],{"trials":1659,"activeCount":98},[],{"trials":1661,"activeCount":98},[1662],{"nctId":417,"briefTitle":418,"status":191,"phases":1663,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":1664,"interventions":1665},[88],[15],[426,427,388,212,428,429,213],{"trials":1667,"activeCount":98},[],{"trials":1669,"activeCount":98},[],{"trials":1671,"activeCount":98},[],{"intervention":429,"totalTrials":9,"cells":1673},{"EARLY_PHASE1":1674,"PHASE1":1676,"PHASE2":1678,"PHASE3":1684,"PHASE4":1686,"NA":1688},{"trials":1675,"activeCount":98},[],{"trials":1677,"activeCount":98},[],{"trials":1679,"activeCount":98},[1680],{"nctId":417,"briefTitle":418,"status":191,"phases":1681,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":1682,"interventions":1683},[88],[15],[426,427,388,212,428,429,213],{"trials":1685,"activeCount":98},[],{"trials":1687,"activeCount":98},[],{"trials":1689,"activeCount":98},[],{"intervention":523,"totalTrials":9,"cells":1691},{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1702,"PHASE4":1704,"NA":1706},{"trials":1693,"activeCount":98},[],{"trials":1695,"activeCount":98},[],{"trials":1697,"activeCount":98},[1698],{"nctId":515,"briefTitle":516,"status":316,"phases":1699,"primaryCompletion":518,"completion":519,"start":45,"enrollment":98,"conditions":1700,"interventions":1701},[88],[24,521],[523,524,481],{"trials":1703,"activeCount":98},[],{"trials":1705,"activeCount":98},[],{"trials":1707,"activeCount":98},[],{"intervention":524,"totalTrials":9,"cells":1709},{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1720,"PHASE4":1722,"NA":1724},{"trials":1711,"activeCount":98},[],{"trials":1713,"activeCount":98},[],{"trials":1715,"activeCount":98},[1716],{"nctId":515,"briefTitle":516,"status":316,"phases":1717,"primaryCompletion":518,"completion":519,"start":45,"enrollment":98,"conditions":1718,"interventions":1719},[88],[24,521],[523,524,481],{"trials":1721,"activeCount":98},[],{"trials":1723,"activeCount":98},[],{"trials":1725,"activeCount":98},[],{"intervention":1727,"totalTrials":9,"cells":1728},"Enzalutamide",{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1733,"PHASE3":1745,"PHASE4":1747,"NA":1749},{"trials":1730,"activeCount":98},[],{"trials":1732,"activeCount":98},[],{"trials":1734,"activeCount":98},[1735],{"nctId":1736,"briefTitle":1737,"status":191,"phases":1738,"primaryCompletion":1739,"completion":1739,"start":1740,"enrollment":195,"conditions":1741,"interventions":1743},"NCT04332744","Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)",[88],"2025-05-06","2020-09-02",[1742],"Metastatic Prostate Cancer",[1727,1744],"Talazoparib",{"trials":1746,"activeCount":98},[],{"trials":1748,"activeCount":98},[],{"trials":1750,"activeCount":98},[],{"intervention":1744,"totalTrials":9,"cells":1752},{"EARLY_PHASE1":1753,"PHASE1":1755,"PHASE2":1757,"PHASE3":1763,"PHASE4":1765,"NA":1767},{"trials":1754,"activeCount":98},[],{"trials":1756,"activeCount":98},[],{"trials":1758,"activeCount":98},[1759],{"nctId":1736,"briefTitle":1737,"status":191,"phases":1760,"primaryCompletion":1739,"completion":1739,"start":1740,"enrollment":195,"conditions":1761,"interventions":1762},[88],[1742],[1727,1744],{"trials":1764,"activeCount":98},[],{"trials":1766,"activeCount":98},[],{"trials":1768,"activeCount":98},[],{"intervention":667,"totalTrials":9,"cells":1770},{"EARLY_PHASE1":1771,"PHASE1":1773,"PHASE2":1775,"PHASE3":1781,"PHASE4":1783,"NA":1785},{"trials":1772,"activeCount":98},[],{"trials":1774,"activeCount":98},[],{"trials":1776,"activeCount":98},[1777],{"nctId":658,"briefTitle":659,"status":191,"phases":1778,"primaryCompletion":661,"completion":662,"start":663,"enrollment":299,"conditions":1779,"interventions":1780},[88],[15,29],[666,667],{"trials":1782,"activeCount":98},[],{"trials":1784,"activeCount":98},[],{"trials":1786,"activeCount":98},[],{"intervention":1788,"totalTrials":9,"cells":1789},"Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]",{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1803,"PHASE4":1805,"NA":1807},{"trials":1791,"activeCount":98},[],{"trials":1793,"activeCount":98},[],{"trials":1795,"activeCount":98},[1796],{"nctId":1797,"briefTitle":1798,"status":326,"phases":1799,"primaryCompletion":1800,"completion":1800,"start":329,"enrollment":25,"conditions":1801,"interventions":1802},"NCT03931551","Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer",[88],"2022-03-02",[18],[1788],{"trials":1804,"activeCount":98},[],{"trials":1806,"activeCount":98},[],{"trials":1808,"activeCount":98},[],{"intervention":321,"totalTrials":9,"cells":1810},{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1815,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1812,"activeCount":98},[],{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":98},[1817],{"nctId":314,"briefTitle":315,"status":316,"phases":1818,"primaryCompletion":318,"completion":318,"start":318,"enrollment":98,"conditions":1819,"interventions":1820},[87,88],[18],[321,200,322],{"trials":1822,"activeCount":98},[],{"trials":1824,"activeCount":98},[],{"trials":1826,"activeCount":98},[],{"intervention":322,"totalTrials":9,"cells":1828},{"EARLY_PHASE1":1829,"PHASE1":1831,"PHASE2":1833,"PHASE3":1839,"PHASE4":1841,"NA":1843},{"trials":1830,"activeCount":98},[],{"trials":1832,"activeCount":98},[],{"trials":1834,"activeCount":98},[1835],{"nctId":314,"briefTitle":315,"status":316,"phases":1836,"primaryCompletion":318,"completion":318,"start":318,"enrollment":98,"conditions":1837,"interventions":1838},[87,88],[18],[321,200,322],{"trials":1840,"activeCount":98},[],{"trials":1842,"activeCount":98},[],{"trials":1844,"activeCount":98},[],{"intervention":1846,"totalTrials":9,"cells":1847},"Temsirolimus",{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1864,"PHASE4":1866,"NA":1868},{"trials":1849,"activeCount":98},[],{"trials":1851,"activeCount":98},[],{"trials":1853,"activeCount":98},[1854],{"nctId":1855,"briefTitle":1856,"status":191,"phases":1857,"primaryCompletion":1858,"completion":1858,"start":1859,"enrollment":1108,"conditions":1860,"interventions":1863},"NCT02093598","POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus",[88],"2014-03","2012-05",[1861,1862],"Carcinoma, Endometrioid","mTOR Protein",[1846],{"trials":1865,"activeCount":98},[],{"trials":1867,"activeCount":98},[],{"trials":1869,"activeCount":98},[],{"intervention":1871,"totalTrials":9,"cells":1872},"Trastuzumab and non-pegylated liposomal doxorubicin",{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1885,"PHASE3":1887,"PHASE4":1889,"NA":1891},{"trials":1874,"activeCount":98},[],{"trials":1876,"activeCount":98},[1877],{"nctId":1878,"briefTitle":1879,"status":191,"phases":1880,"primaryCompletion":1581,"completion":1581,"start":1881,"enrollment":1882,"conditions":1883,"interventions":1884},"NCT02562378","T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer",[87],"2015-10",15,[15],[1871],{"trials":1886,"activeCount":98},[],{"trials":1888,"activeCount":98},[],{"trials":1890,"activeCount":98},[],{"trials":1892,"activeCount":98},[],{"intervention":1894,"totalTrials":33,"cells":1895},"Olaparib",{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1900,"PHASE3":1912,"PHASE4":1914,"NA":1916},{"trials":1897,"activeCount":98},[],{"trials":1899,"activeCount":98},[],{"trials":1901,"activeCount":98},[1902],{"nctId":1903,"briefTitle":1904,"status":326,"phases":1905,"primaryCompletion":1906,"completion":1907,"start":1908,"enrollment":1909,"conditions":1910,"interventions":1911},"NCT03367689","A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent",[88],"2021-07-31","2021-12-31","2018-04-17",7,[15],[1894],{"trials":1913,"activeCount":98},[],{"trials":1915,"activeCount":98},[],{"trials":1917,"activeCount":98},[1918],{"nctId":1919,"briefTitle":1920,"status":191,"phases":1921,"primaryCompletion":1922,"completion":1923,"start":1924,"enrollment":1925,"conditions":1926,"interventions":1928},"NCT02506816","Preoperative Olaparib Endometrial Carcinoma Study (POLEN)",[],"2018-07","2019-03","2016-02",36,[1927],"Endometrial Carcinoma",[1894],{"intervention":1930,"totalTrials":9,"cells":1931},"Fulvestrant Injectable Product",{"EARLY_PHASE1":1932,"PHASE1":1934,"PHASE2":1936,"PHASE3":1938,"PHASE4":1940,"NA":1942},{"trials":1933,"activeCount":98},[],{"trials":1935,"activeCount":98},[],{"trials":1937,"activeCount":98},[],{"trials":1939,"activeCount":98},[],{"trials":1941,"activeCount":98},[],{"trials":1943,"activeCount":98},[1944],{"nctId":1945,"briefTitle":1946,"status":191,"phases":1947,"primaryCompletion":1948,"completion":1949,"start":1950,"enrollment":1951,"conditions":1952,"interventions":1954},"NCT06525675","Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)",[],"2024-05-26","2024-09-02","2022-07-18",419,[21,18,1953,35,115],"Luminal Breast Cancer",[1930,1955,1956],"Letrozole 2.5mg","Palbociclib 125mg",{"intervention":1955,"totalTrials":9,"cells":1958},{"EARLY_PHASE1":1959,"PHASE1":1961,"PHASE2":1963,"PHASE3":1965,"PHASE4":1967,"NA":1969},{"trials":1960,"activeCount":98},[],{"trials":1962,"activeCount":98},[],{"trials":1964,"activeCount":98},[],{"trials":1966,"activeCount":98},[],{"trials":1968,"activeCount":98},[],{"trials":1970,"activeCount":98},[1971],{"nctId":1945,"briefTitle":1946,"status":191,"phases":1972,"primaryCompletion":1948,"completion":1949,"start":1950,"enrollment":1951,"conditions":1973,"interventions":1974},[],[21,18,1953,35,115],[1930,1955,1956],{"intervention":1956,"totalTrials":9,"cells":1976},{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1981,"PHASE3":1983,"PHASE4":1985,"NA":1987},{"trials":1978,"activeCount":98},[],{"trials":1980,"activeCount":98},[],{"trials":1982,"activeCount":98},[],{"trials":1984,"activeCount":98},[],{"trials":1986,"activeCount":98},[],{"trials":1988,"activeCount":98},[1989],{"nctId":1945,"briefTitle":1946,"status":191,"phases":1990,"primaryCompletion":1948,"completion":1949,"start":1950,"enrollment":1951,"conditions":1991,"interventions":1992},[],[21,18,1953,35,115],[1930,1955,1956]]